Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy
Chimeric antigen receptor (CAR) T therapy has shown remarkable success in discovering novel CAR-T cell products for treating malignancies. Despite of successful results from clinical trials, CAR-T cell therapy is ineffective for long-term disease progression. Numerous challenges of CAR-T cell immuno...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Elsevier Inc.
2023
|
| Subjects: |
| _version_ | 1796867822017576960 |
|---|---|
| author | Muhammad Naeem, Muhammad Naeem Abu Hazafa, Abu Hazafa Naheed Bano, Naheed Bano Rashid Ali, Rashid Ali Muhammad Farooq, Muhammad Farooq Abd. Razak, Saiful Izwan Lee, Tze Yan Devaraj, Sutha |
| author_facet | Muhammad Naeem, Muhammad Naeem Abu Hazafa, Abu Hazafa Naheed Bano, Naheed Bano Rashid Ali, Rashid Ali Muhammad Farooq, Muhammad Farooq Abd. Razak, Saiful Izwan Lee, Tze Yan Devaraj, Sutha |
| author_sort | Muhammad Naeem, Muhammad Naeem |
| collection | ePrints |
| description | Chimeric antigen receptor (CAR) T therapy has shown remarkable success in discovering novel CAR-T cell products for treating malignancies. Despite of successful results from clinical trials, CAR-T cell therapy is ineffective for long-term disease progression. Numerous challenges of CAR-T cell immunotherapy such as cell dysfunction, cytokine-related toxicities, TGF-β resistance, GvHD risks, antigen escape, restricted trafficking, and tumor cell infiltration still exist that hamper the safety and efficacy of CAR-T cells for malignancies. The accumulated data revealed that these challenges could be overcome with the advanced CRISPR genome editing technology, which is the most promising tool to knockout TRAC and HLA genes, inhibiting the effects of dominant negative receptors (PD-1, TGF-β, and B2M), lowering the risks of cytokine release syndrome (CRS), and regulating CAR-T cell function in the tumor microenvironment (TME). CRISPR technology employs DSB-free genome editing methods that robustly allow efficient and controllable genetic modification. The present review explored the innovative aspects of CRISPR/Cas9 technology for developing next-generation/universal allogeneic CAR-T cells. The present manuscript addressed the ongoing status of clinical trials of CRISPR/Cas9-engineered CAR-T cells against cancer and pointed out the off-target effects associated with CRISPR/Cas9 genome editing. It is concluded that CAR-T cells modified by CRISPR/Cas9 significantly improved antitumor efficacy in a cost-effective manner that provides opportunities for novel cancer immunotherapies. |
| first_indexed | 2024-04-20T15:24:51Z |
| format | Article |
| id | utm.eprints-105242 |
| institution | Universiti Teknologi Malaysia - ePrints |
| last_indexed | 2024-04-20T15:24:51Z |
| publishDate | 2023 |
| publisher | Elsevier Inc. |
| record_format | dspace |
| spelling | utm.eprints-1052422024-04-17T06:20:02Z http://eprints.utm.my/105242/ Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy Muhammad Naeem, Muhammad Naeem Abu Hazafa, Abu Hazafa Naheed Bano, Naheed Bano Rashid Ali, Rashid Ali Muhammad Farooq, Muhammad Farooq Abd. Razak, Saiful Izwan Lee, Tze Yan Devaraj, Sutha Q Science (General) R Medicine (General) TK Electrical engineering. Electronics Nuclear engineering Chimeric antigen receptor (CAR) T therapy has shown remarkable success in discovering novel CAR-T cell products for treating malignancies. Despite of successful results from clinical trials, CAR-T cell therapy is ineffective for long-term disease progression. Numerous challenges of CAR-T cell immunotherapy such as cell dysfunction, cytokine-related toxicities, TGF-β resistance, GvHD risks, antigen escape, restricted trafficking, and tumor cell infiltration still exist that hamper the safety and efficacy of CAR-T cells for malignancies. The accumulated data revealed that these challenges could be overcome with the advanced CRISPR genome editing technology, which is the most promising tool to knockout TRAC and HLA genes, inhibiting the effects of dominant negative receptors (PD-1, TGF-β, and B2M), lowering the risks of cytokine release syndrome (CRS), and regulating CAR-T cell function in the tumor microenvironment (TME). CRISPR technology employs DSB-free genome editing methods that robustly allow efficient and controllable genetic modification. The present review explored the innovative aspects of CRISPR/Cas9 technology for developing next-generation/universal allogeneic CAR-T cells. The present manuscript addressed the ongoing status of clinical trials of CRISPR/Cas9-engineered CAR-T cells against cancer and pointed out the off-target effects associated with CRISPR/Cas9 genome editing. It is concluded that CAR-T cells modified by CRISPR/Cas9 significantly improved antitumor efficacy in a cost-effective manner that provides opportunities for novel cancer immunotherapies. Elsevier Inc. 2023-03-01 Article PeerReviewed Muhammad Naeem, Muhammad Naeem and Abu Hazafa, Abu Hazafa and Naheed Bano, Naheed Bano and Rashid Ali, Rashid Ali and Muhammad Farooq, Muhammad Farooq and Abd. Razak, Saiful Izwan and Lee, Tze Yan and Devaraj, Sutha (2023) Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy. Life Sciences, 316 (NA). NA. ISSN 0024-3205 http://dx.doi.org/10.1016/j.lfs.2023.121409 DOI:10.1016/j.lfs.2023.121409 |
| spellingShingle | Q Science (General) R Medicine (General) TK Electrical engineering. Electronics Nuclear engineering Muhammad Naeem, Muhammad Naeem Abu Hazafa, Abu Hazafa Naheed Bano, Naheed Bano Rashid Ali, Rashid Ali Muhammad Farooq, Muhammad Farooq Abd. Razak, Saiful Izwan Lee, Tze Yan Devaraj, Sutha Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy |
| title | Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy |
| title_full | Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy |
| title_fullStr | Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy |
| title_full_unstemmed | Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy |
| title_short | Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy |
| title_sort | explorations of crispr cas9 for improving the long term efficacy of universal car t cells in tumor immunotherapy |
| topic | Q Science (General) R Medicine (General) TK Electrical engineering. Electronics Nuclear engineering |
| work_keys_str_mv | AT muhammadnaeemmuhammadnaeem explorationsofcrisprcas9forimprovingthelongtermefficacyofuniversalcartcellsintumorimmunotherapy AT abuhazafaabuhazafa explorationsofcrisprcas9forimprovingthelongtermefficacyofuniversalcartcellsintumorimmunotherapy AT naheedbanonaheedbano explorationsofcrisprcas9forimprovingthelongtermefficacyofuniversalcartcellsintumorimmunotherapy AT rashidalirashidali explorationsofcrisprcas9forimprovingthelongtermefficacyofuniversalcartcellsintumorimmunotherapy AT muhammadfarooqmuhammadfarooq explorationsofcrisprcas9forimprovingthelongtermefficacyofuniversalcartcellsintumorimmunotherapy AT abdrazaksaifulizwan explorationsofcrisprcas9forimprovingthelongtermefficacyofuniversalcartcellsintumorimmunotherapy AT leetzeyan explorationsofcrisprcas9forimprovingthelongtermefficacyofuniversalcartcellsintumorimmunotherapy AT devarajsutha explorationsofcrisprcas9forimprovingthelongtermefficacyofuniversalcartcellsintumorimmunotherapy |